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Abstract
Aims/hypothesis The aim of this work was to examine the relationship between family history of type 1 diabetes, birthweight,
growth during the first 2 years and development of multiple beta cell autoantibodies in children with a first-degree relative with
type 1 diabetes and HLA-conferred disease susceptibility.
Methods In a secondary analysis of the Trial to Reduce IDDM in the Genetically at Risk (TRIGR), clinical characteristics and
development of beta cell autoantibodies were compared in relation to family history of type 1 diabetes (mother vs father vs
sibling) in 2074 children from families with a single affected family member.
Results Multiple autoantibodies (≥2 of 5 measured) developed in 277 (13%) children: 107 (10%), 114 (16%) and 56 (18%) born
with a mother, father or sibling with type 1 diabetes, respectively (p < 0.001). The HR for time to multiple autoimmunity was 0.54
(95%CI 0.39, 0.75) in offspring of affected mothers (n = 107/1046, p < 0.001) and 0.81 (95%CI 0.59, 1.11) (n = 114/722, p = 0.19)
in offspring of affected fathers, compared with participants with a sibling with type 1 diabetes (comparator group n = 56/306). The
time to the first autoantibody present (to insulin, GAD, tyrosine phosphatase-related insulinoma-associated 2 molecules, islet cell or
zinc transporter 8) was similar in the three groups. Height velocity (z score/year) in the first 24months was independently associated
with developing multiple antibodies in the total cohort (HR 1.31 [95% CI 1.01, 1.70], p = 0.04). A higher birthweight in children
born to an affected mother vs affected father or an affected sibling was not related to the risk of multiple autoimmunity.
Conclusions/interpretation The risk of developing multiple autoantibodies was lower in children with maternal type 1 diabetes.
For the whole group, this risk of developingmultiple autoantibodies was independent of birthweight but was greater in those with
increased height velocity during the first 2 years of life. However, the risk associated with paternal type 1 diabetes was not linked
to differences in birthweight or early growth.
Trial registration ClinicalTrials.gov NCT00179777
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Type 1 diabetes is one of the most prevalent chronic diseases in
childhood. Its incidence is rapidly increasing worldwide [1–5].
Type 1 diabetes is caused by a progressive but heterogeneous
autoimmune destruction of the beta cells resulting in lack of
insulin. Both genetic and environmental factors contribute to
this process, although its pathophysiology is poorly understood
[6]. Historically, the risk of diabetes in the offspring of fathers
with type 1 diabetes has been reported as being higher than that
in the offspring of mothers with type 1 diabetes or in those with
siblings who have type 1 diabetes [7]. Many researchers have
examined the link between birthweight and risk of either type 1
diabetes or beta cell autoimmunity with variable results. This
may reflect the heterogeneity of the sample size, study popula-
tion and methodology used. However, a large meta-analysis of
29 studies predominantly from European centres, found that the
risk of type 1 diabetes was significantly higher in children with
greater birthweights [8]. Larger studies, looking specifically at
individuals genetically at risk for type 1 diabetes, observed that
greater birthweight is related to development of type 1 diabetes
[9, 10] or beta cell autoimmunity [10] and that this pattern is
similar across different geographical regions. Furthermore,
some studies that were able to prospectively observe children
with genetic risk for type 1 diabetes have identified rapid linear
growth during infancy as a risk factor for the development of
beta cell autoimmunity and type 1 diabetes [11–14].
Although The Environmental Determinants of Diabetes in
the Young (TEDDY) study group recently reported that fami-
ly history is not a significant risk factor for the progression to
diabetes in individuals who develop multiple autoantibodies
[15], their previous reports focusing on growth and risk beta
cell autoimmunity, did not account for first-degree relative
status in their analysis [16]. However, a recent analysis exam-
ining the effect of interactions between genetic and environ-
mental factors on the development of islet cell autoimmunity
and diabetes indicated that family history (father or sibling vs
no family history) significantly influenced both, while weight
at 12 months only affected development of autoimmunity but
not type 1 diabetes [17]. To our knowledge, none of the stud-
ies looking at birthweight, infant growth, HLA typing and risk
of beta cell autoimmunity evaluated possible differences in
risk linked to birthweight, infant growth and autoimmunity
associated with the proband (father, mother or sibling). In fact,
many of these studies excluded maternal diabetes from the
analysis in order to avoid the confounding factor associated
with maternal metabolic control and birthweight. In this study
we examined the relationship between the family history of
type 1 diabetes (mother vs father vs sibling), birthweight and
initial 2 year growth and autoimmunity in a cohort of 2074
participants with one first-degree relative with type 1 diabetes
in the Trial to Reduce IDDM in the Genetically at Risk
(TRIGR) study (ClinicalTrials.gov registration no.
NCT00179777).
Methods
Study design and participants
The TRIGR studywas an international double-blinded clinical
trial designed to determine whether weaning to a hydrolysed
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infant formula vs a conventional cow’s milk-based formula
reduces the cumulative incidence of diabetes-associated auto-
antibodies and the incidence of diabetes in young children
with a first-degree relative with type 1 diabetes and increased
HLA-conferred genetic risk. The trial was approved in all
participating TRIGR centres by the Ethics Institutional
Review Boards or Committees of Human Experimentation
and informed consent was obtained for each participating
child. A full description of the TRIGR study design has been
published previously [18]. Children at increased risk for
developing type 1 diabetes were recruited for the trial before
or at birth between May 2002 and January 2007 (n = 2159)
and were monitored until February 2017, when all children
were at least 10 years of age, for the frequency of beta cell
autoantibodies and/or the development of type 1 diabetes. For
the purpose of this secondary analysis, we excluded 73 chil-
dren with more than one first-degree family member with type
1 diabetes: ten with mother and sibling; 33 with father and
sibling; 29 with both mother and father; and one with a moth-
er, father and sibling with type 1 diabetes. Another four were
excluded because of missing family relationship status and
eight were excluded due to missing antibody data.
Data collection Only data collected during the conduct of the
original TRIGR study was used for this secondary analysis.
Demographic characteristics, including sex, race, ethnicity
and data on type 1 diabetes in first-degree relatives, were
obtained at the time of enrolment or birth. HLA genotyping
to determine eligibility was performed [19]. Anthropometric
indices were obtained at birth and at regular intervals (values
at 3, 6, 9, 12, 18 and 24 months of age are included in this
analysis). Weight velocity (kg/year) and length/height veloc-
ity (cm/year), as well as corresponding z score values calcu-
lated from 2000 CDC growth charts [20], were recorded for
the first 2 years of life. BMI (kg/m2) was calculated at 2 years
of age. The definition of exclusive breastfeeding was intake of
only breast milk (banked or mother’s own), supplementary
vitamins or minerals or water. The presence of beta cell auto-
antibodies was determined in a central laboratory (Scientific
Laboratory, Children’s Hospital, University of Helsinki,
Helsinki, Finland) at birth and at 3, 6, 9, 12, 18 and 24 months
of age and annually thereafter. Islet cell autoantibodies (ICA)
were measured using indirect immunofluorescence with a cut-
off of 2.5 JDRF units [19] and GAD autoantibodies (GADA),
tyrosine phosphatase-related insulinoma-associated 2 mole-
cule autoantibodies (IA-2A), insulin autoantibodies (IAA)
and zinc transporter 8 autoantibodies (ZnT8A) were analysed
with specific radiobinding assays with cut-off limits of 5.36
RU, 0.77 RU, 2.80 RU and 0.61 RU, respectively [21].
Development of an autoantibody was defined as the first
occurrence of a result above the specified cut-off limits. The
disease-specific sensitivity and specificity for each were previ-
ously reported [19, 22]. Maternal antibodies that were
placentally transferred, as verified by their decreasing levels
and disappearance from the child’s circulation by age
18 months, were not included in the statistical analysis.
Statistical analysis
We compared demographic, clinical and anthropometric char-
acteristics by family history of type 1 diabetes (mother vs
father vs sibling) univariately using the χ2 test for categorical
variables and ANOVA for continuous variables. Cox propor-
tional hazard univariate model was used to analyse the rela-
tionship between family history of type 1 diabetes (mother vs
father vs sibling) and time to multiple autoimmunity (defined
as two or more autoantibodies), positivity for GADA, IAA,
IA-2A, ICA and ZnT8A and development of clinical type 1
diabetes. Multivariate Cox proportional hazard regression
models were created to predict time to antibodies (multiple
autoantibodies, GADA, IAA, IA-2A, ICA or ZnT8A) and
the development of clinical type 1 diabetes in each family
history group (mother vs father vs sibling). The following
variables thought to be clinically important were selected a
priori: country of birth, sex, HLA risk group, mode of deliv-
ery, birth length, birthweight, treatment group, height velocity
in the first 24 months of life (cm/year), weight velocity in first
24 months of life (z score), BMI z score at 24 months of life,
infant diet in the first days of life, and length of exclusive
breastfeeding. These were then included in a stepwise model
when found to be statistically significant. Using the same
covariates listed above, general linear regression models
(GLMs) were used to examine the difference between the
three groups of origin of the proband in linear growth both
in cm/year and z score/year. All HRs are presented with the
sibling group as the reference group. A p value of <0.05 was
considered statistically significant for the comparisons
between the three groups. All participants with missing data
specified as part of a particular analysis were omitted from that
analysis. No imputation of data was performed. All analyses
were conducted using SAS version 9.4, USA. All results
presented in the Results section are new and were not part of
previous TRIGR reports.
Results
Beta cell autoimmunity and relationship to family history of
type 1 diabetes The clinical characteristics of the 2074 chil-
dren with a single first-degree relative with type 1 diabetes are
presented in Table 1. During the study period, positive sero-
conversion occurred in 933 (45%) children, which included
346 (17%) with GADA, 319 (15%) with IAA, 196 (9%) with
IA-2A, 724 (35%) with ICA and 171 (8%) with ZnT8A.
Multiple autoantibodies (two or more of GADA, IA-2A,
IAA, ZnT8A and ICA) developed in 277 (13%) children:
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107 (10%), 114 (16%) and 56 (18%) of children born with a
mother, father or sibling with type 1 diabetes, respectively.
Time to the development of multiple autoantibodies in the
child differed significantly between those with an affected
mother, father or sibling (time to 10% cumulative incidence
[95% CI]: mothers 9.3 years [7.7, 11.3]; fathers 6.3 years [5.2,
7.6]; sibling 5.0 years [3.9, 6.5]) (logrank χ2 16.2, p < 0.001)
(Fig. 1a). Pairwise comparisons between the three groups indi-
cated that while there was not a significant difference in the
progression to multiple autoantibodies between those with an
affected father and sibling (logrank χ2 1.7, p = 0.189), there
was a significant difference between those with an affected
mother and, respectively, those with an affected father
(logrank χ2 8.7, p = 0.003) and those with an affected sibling
(logrank χ2 14.0, p < 0.001).
First positive beta cell autoantibody and relationship of fami-
ly member affected by type 1 diabetes In children developing
multiple antibodies, the first was GADA in 52 (19%), IAA in
48 (18%), ICA in 46 (17%), IA-2A in three (1%) and ZnT8A
in three (1%). Multiple antibodies occurred in the first positive
sample in 119 (44%). Among the 119 children who developed
multiple antibodies in the first sample, 59% tested positive for
GADA, 52% for IAA, 62% for ICA, 27% for IA-2A and 21%
for ZnT8A, respectively. There was no difference in which
antibody appeared first between the three groups (p = 0.39).
Times to each antibody as the first antibody present were
similar in all three groups (logrank χ2 0.5–5.5; all p > 0.05)
(Fig. 1b–f).
Association between birth and growth variables and affected
family member relationshipDespite early differences in mode
of delivery, gestational age, birthweight, birth length and dura-
tion of exclusive breastfeeding (see Table 1), univariate anal-
ysis demonstrated at age 24 months only mild non-significant
differences in BMI z score (ESM Fig. 1, p = 0.054), height
velocity (ESM Fig. 2a, p = 0.053) between the three groups.
However, there was a significant difference between the three
groups in height velocity z score (ESM Fig. 2b, p = 0.041),
explained by a wider variation in growth seen in children born
to a father with diabetes. GLMs predicting height velocity
either as cm/year (Model 1, ESM Table 1) or z score per year
(Model 2, ESM Table 1) until age 24 months by relative with
type 1 diabetes resulted in significant differences: height
velocity in cm/year R2 was 0.246 with F (13, 1754) = 44.0;
p < 0.001, while for height velocity in z score/year R2 was
0.399 with F (13, 1754) = 89.5; p < 0.001. Variables found
to contribute to each model were similar between the two
GLM models (birth length, birthweight, mother with type 1
diabetes, region of origin, duration of exclusive breast feeding,
being fed only infant formula in the first week of life vs other
types of first diet, birth order and gestational age) (ESM
Table 1). In both models, the relative with type 1 diabetes
showed a statistically significant but minor association:
infants of an affected mother explained <1% of the variation
in growth. Re-enforcing this point, removing family history as
a variable in these models produced remarkably similar
results, with R2 values of 0.237 and 0.391 for the models for
height velocity in cm/year and z score/year, respectively).
Association between the development of multiple autoanti-
bodies, family member with type 1 diabetes and first 2 years
of physical growth When Cox proportional hazard stepwise
multivariatemodelling for time tomultiple autoimmunitywith
an a priori inclusion of family member with type 1 diabetes
was used, being born to a mother with type 1 diabetes
remained the lowest risk of developing multiple antibodies
(HR 0.70 [95% CI 0.49, 1.01], p = 0.055) compared with an
affected father or sibling (Table 2). The other significant vari-
ables retained in this model were HLA risk 1 (HR 1.74 [95%
CI 1.33, 2.28], p < 0.001), birth length (HR 1.09 [95% CI
1.03, 1.16], p = 0.004) and height velocity z scores in the first
24 months (HR 1.31 [95% CI 1.01, 1.70], p = 0.041).
Association between risk of type 1 diabetes and relationship
of affected family member The time to the development of
type 1 diabetes was compared between the three groups of
family member with type 1 diabetes. Univariate analyses indi-
cated that there was an overall difference between the groups
(time to 5% cumulative incidence [95% CI]: mothers
10.0 years [7.7, 12.9]; fathers 6.9 years [5.4, 8.9]; sibling
4.3 years [3.1, 5.9]) (logrank χ2 17.2, p < 0.001) (ESM
Fig. 3). When Cox proportional hazard stepwise multivar-
iate modelling for time to development of type 1 diabetes
with an a priori inclusion of family member with type 1
diabetes was used, those with a mother, compared with an
affected father or sibling, with type 1 diabetes remained at
lowest risk of developing type 1 diabetes (HR 0.58 [95%
CI 0.36, 0.93], p = 0.02). The other significant variables
retained in this model were HLA risk 1 (HR 2.21 [95%
CI 1.54, 3.16)], p < 0.001) and height velocity z score in
the first 24 months (HR 1.41 [95% CI 1.10, 1.82], p
< 0.01) (Table 3).
Discussion
In this large international cohort of children genetically at risk
for type 1 diabetes followed for more than 8 years, we
confirmed prior data showing that the risk of developing
multiple autoantibodies was lower when children were born
to mothers with type 1 diabetes compared with those having
an affected father [23] or an affected sibling [24]. We were
able to search for potential differences in demographics or
patterns of autoimmunity that could help explain this
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difference. We observed no difference in the type of autoan-
tibody appearing first between the three groups.
Despite differences in birth demographics among these
three groups of relatives, this differential risk was not related
to birthweight or linear growth (height and BMI) in the first
24 months of life. In single correlations, the children born to a
mother with type 1 diabetes did have a higher birthweight and
lower birth length. Based on the prediction growthmodels, the
children with higher birthweight and lower birth length grew
faster in the first 24 months. Maternal diabetes had a negative
but minimal impact on growth during the first 24 months.
Hence, based on the growth models, we would have expected
these children to have increased risk of developing multiple
autoantibodies. Yet, the Cox proportional hazard stepwise
multivariate modelling for time to multiple autoimmunity
showed that although those with increased birth length and
growth velocity developed multiple autoantibodies sooner,
children born to a mother with type 1 diabetes were less likely
to develop multiple autoantibodies. Because of the differing
results of the single correlations and the two predictive
models, we conclude that the risk related to family history
was not explained by differences in birthweight or growth
during the first 2 years between the groups.
Three studies that specifically evaluated differences in
number and type of measured autoantibodies in offspring of
mothers compared with fathers with type 1 diabetes also
reported that children with a father with type 1 diabetes were
more likely to developmultiple autoantibodies than those with
a mother with diabetes [23, 25, 26]. In contrast to our TRIGR
study, these three studies did not account for HLA type risk
Table 1 Demographic, clinical
and anthropometric characteris-
tics by family history of type 1










Male sex, n (%) 547 (52) 391 (54) 156 (51) NS
Birth ordera 1 (1) 1 (1) 2 (1) <0.001
Birthweight, kg 3.65 ± 0.60 3.56 ± 0.49 3.57 ± 0.49 0.004
Birth length, cm 50.9 ± 3.0 51.0 ± 2.4 51.6 ± 2.7 <0.001
Weight at 24 months, cm 12.8 ± 1.6 12.9 ± 1.4 12.9 ± 1.7 0.627
Weight at 24 months, z score 0.2 ± 1.1 0.3 ± 1.0 0.2 ± 1.2 0.346
BMI at 24 months, z score 0.08 ± 1.15 −0.03 ± 1.04 −0.15 ± 1.17 0.054
Height velocity at 24 months, cm/year 18.3 ± 2.0 18.5 ± 1.9 18.2 ± 1.8 0.053
Height velocity at 24 months, z score −0.04 ± 0.66 0.00 ± 0.61 −0.011 ± 0.56 0.041
bHLA risk type, n (%) 0.017
HLA risk 1 229 (22) 171 (24) 95 (31)
HLA risk 2 456 (44) 336 (47) 117 (38)
HLA risk 3 350 (34) 210 (29) 92 (30)
HLA risk 4 11 (1) 5 (1) 2 (1)
Length of exclusive breastfeeding,
months
0.7 ± 1.6 1.8 ± 2.2 2.3 ± 2.3 <0.001
Caesarean section, n (%) 642 (61.4) 183 (25.3) 74 (24.2) <0.001
Gestational age, weeks 37.8 ± 1.3 39.8 ± 1.4 39.4 ± 1.4 <0.001
Autoantibodies, n (%)
Multiple 107 (10) 114 (16) 56 (18) <0.001
IAA 139 (13) 110 (15) 70 (23) <0.001
GADA 154 (15) 126 (18) 66 (22) 0.015
IA-2A 72 (7) 85 (12) 39 (13) <0.001
ZnT8A 65 (6) 75 (10) 31 (10) 0.003
ICA 337 (32) 270 (37) 117 (38) 0.034
Type 1 diabetes, n (%) 59 (6) 60 (8) 38 (12) <0.001
Follow-up time, years 9.1 ± 4.3 9.4 ± 4.0 8.7 ± 4.3 0.032
Values are expressed as mean±SD or n (%)
a Values are expressed as median (IQR)
bHLA risk 1, HLA-DQB1*02/DQB1*03:02; HLA risk 2, HLA-DQB1*03:02/x (x not DQB1*02, DQB1*03:01
or DQB1*06:02); HLA risk 3, HLA-DQA1*05-DQB1*02/y (y not DQA1*02:01-DQB1*02, DQB1*03:01,
DQB1*06:02 or DQB1*06:03); HLA risk 4, HLA-DQA1*03-DQB1*02/y (y not DQA1*02:01-DQB1*02,
DQB1*03:01, DQB1*06:02 or DQB1*06:03)
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Fig. 1 Time to presence of autoantibodies by family history (mother vs
father vs sibling): multiple autoantibodies defined as two or more anti-
bodies (logrank χ2 16.2, p < 0.001) (a); GADA as first antibody (logrank
χ2 4.8, p = 0.090) (b); IAA as first antibody (logrank χ2 5.5, p = 0.064)
(c); IA-2A as first antibody (logrank χ2 0.55, p = 0.761) (d); ZnT8A as
first antibody (logrank χ2 0.6, p = 0.73) (e); and ICA as first antibody
(logrank χ2 1.2, p = 0.55) (f)
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stratification and therefore included both high and lower risk
HLA groups. The similar finding of significantly higher rates
of multiple autoantibodies when the father had type 1 diabetes
in our cohort of young children with a first-degree relative
with type 1 diabetes and increased HLA-conferred genetic risk
suggests that HLA-conferred genetic risk also is not the expla-
nation of the observed differences.
Although different rates of progression to type 1 diabetes
have been reported depending on which autoantibody appears
first [27], we observed no specific difference in the first-
Table 2 HR (95% CI) from
univariate and multivariate Cox
time to development of multiple
autoantibodies model
Variable Univariate models Multivariate model
HR (95% CI) p
value
HR (95% CI) p
value
Family history from mother 0.54 (0.39, 0.75) <0.001 0.70 (0.49, 1.01) 0.055
Family history from father 0.81 (0.59, 1.11) 0.191 0.93 (0.65, 1.33) 0.682
HLA risk 1a 1.92 (1.50, 2.45) <0.001 1.74 (1.33, 2.28) <0.001
Birth length 1.06 (1.01, 1.11) 0.012 1.09 (1.03, 1.16) 0.004
Height velocity (z score) 1.03 (0.84, 1.27) 0.758 1.31 (1.01, 1.70) 0.041
Weight velocity (z score) 1.02 (0.84, 1.23) 0.880
Male sex 1.27 (1.00, 1.61) 0.054
Birthweight 1.08 (0.87, 1.33) 0.494
Gestational age, weeks 1.05 (0.98, 1.13) 0.168
Region of origin
Northern Europe 1.11 (0.85, 1.45) 0.449
Central Europe 1.10 (0.76, 1.58) 0.614
Vaginal delivery 1.24 (0.97, 1.58) 0.084
Treatment group assignment casein hydrosylate
formula
1.13 (0.89, 1.43) 0.314
Exclusive breastfeeding duration 1.05 (1.00, 1.11) 0.071
Birth order 1.06 (0.95, 1.18) 0.314
aHLA-DQB1*02/DQB1*03:02
Table 3 HR (95% CI) from
univariate and multivariate Cox
time to the development type 1
diabetes model
Variable Univariate models Multivariate model
HR (95% CI) p
value
HR (95% CI) p
value
Family history from mother 0.43 (0.29, 0.65) <0.001 0.58 (0.36, 0.93) 0.023
Family history from father 0.62 (0.41, 0.93) 0.021 0.67 (0.41, 1.09) 0.104
HLA risk 1a 2.35 (1.71, 3.24) <0.001 2.21 (1.54, 3.16) <0.001
Height velocity (z score) 1.38 (1.07, 1.78) 0.012 1.41 (1.10, 1.82) 0.007
Birth length 1.01 (0.95, 1.07) 0.732
Weight velocity, z score 1.40 (1.06, 1.84) 0.017
Male sex 1.07 (0.78, 1.46) 0.682
Birthweight 0.99 (0.74, 1.31) 0.930
Gestational age, weeks 1.03 (0.94, 1.14) 0.539
Region of origin
Northern Europe 1.09 (0.77, 1.56) 0.625
Central Europe 1.02 (0.62, 1.67) 0.936
Vaginal delivery 1.28 (0.93, 1.77) 0.132
Treatment group assignment, casein hydrosylate
formula
1.06 (0.78, 1.45) 0.717
Exclusive breastfeeding duration 1.05 (0.98, 1.13) 0.183
Birth order 1.08 (0.93, 1.25) 0.307
aHLA-DQB1*02/DQB1*03:02
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appearing antibody according to type for a first-degree relative
with diabetes in this large cohort. The German BABY-DIAB
study [26] also reported no specific order in which autoanti-
body developed first according to which relative had diabetes.
Hence this lower risk associated with being born to a mother
with type 1 diabetes is not explained by a differing pattern in
which antibody appears first.
Multiple studies, including a recent meta-analysis, have
reported a link between greater birthweight and the risk of
type 1 diabetes [8] or islet cell autoimmunity [10]. In contrast,
Bonifacio et al [25] reported that in infants of a mother with
type 1 diabetes, those in the lower and upper tertiles for
birthweight as well as the presence of a moderately elevated
third-trimester maternal HbA1c, had a lower risk of autoim-
munity to beta cells. In our cohort, children of mothers with
type 1 diabetes had greater birthweight and an earlier gesta-
tional age but no relationship was shown between their
birthweight and risk of multiple autoantibodies. Hence, in
our study, the relative protective effect provided by having a
mother with type 1 diabetes, compared with a father or sibling
with type 1 diabetes, seems not to be mediated through
birthweight.
The accelerator hypothesis [28] suggests that the increasing
incidence rate of type 1 diabetes is related to increasing rates
of childhood obesity and insulin resistance. In the Australian
BABY-DIAB study [11], weight and BMI z score were found
to be associated with higher rates of islet autoimmunity. Rapid
linear growth during infancy has been identified as a risk
factor for the development of autoimmunity and type 1 diabe-
tes [11–13, 29]. A recent report from the TEDDY cohort
found an increased risk of progression from autoimmunity to
type 1 diabetes with lower height growth in infancy but
increased weight gain and height gain in early childhood
[30]. Similarly, we found that increased birth length and linear
height velocity z scores in the first 2 years of life were inde-
pendently associated with the development of multiple auto-
antibodies. Although the TRIGR Study Group [31] had previ-
ously reported higher BMI at 5 years in Canadian girls born to
a mother with type 1 diabetes, we did not find any significant
differences in BMI at 24 months between the three groups
based on the family history in the current analysis.
In this analysis, we also found a significant difference in the
risk of developing type 1 diabetes in children born to mothers
with type 1 diabetes compared with children with fathers or
siblings with type 1 diabetes. Previously, the TRIGR Study
Group [32] reported that there was no significant effect of type
of family history on the development of type 1 diabetes in the
TRIGR cohort. However, that analysis compared children with
a parent only (mother and fathers were combined) to those with
sibling only or those with an affected sibling and parent.
This study has some strengths. Although the TEDDY study
group [33] recruited more than 8600 children, only about 10%
were from a first-degree-relative family, which remains fewer
than TRIGR (n = 2074). Our cohort, including 277 children
who developed multiple beta cell autoantibodies, is one of the
largest to date to explore the influence of type of family
history on the development of islet cell autoimmunity.
The inclusion criteria were based on presence of a first-
degree relative with type 1 diabetes and genetic (HLA)
risk stratification at birth in an international multicentre,
rather than country-specific, study. Data on five differ-
ent autoantibodies serially measured through a follow-up
period allowed for new comparisons of both type and
timing of autoantibodies between the three family histo-
ry groupings.
Some limitations should be considered when interpreting
our results. The study presented here is based on a posteriori
analysis, which cannot allow us to fully differentiate HLA
effect from family history effect. The intentional wide
geographical and ethnic background of the study population
may have introduced significant environmental variables that
could have influenced the results. We only analysed growth
data from the first 24 months of life. It is possible that later
growth velocity has more impact on progression to type 1
diabetes. However, this analysis was beyond the scope of this
paper. Another point to consider when comparing our results
with those of other studies is the definition used for multiple
antibodies: defined as two or more autoantibodies present in
each sample of IAA, GADA, IA-2A, ICA and ZnT8A. Some
studies define this as at least two different time points with
positive results and others have not included ICA in this defi-
nition due to concerns of overlapping measurements with
GADA and IA-2A. The definition used in this paper was set
at the start of the TRIGR study and has been used consistently
in all its publications. Hence, the results presented may not be
comparable with those of studies wherein a different defini-
tion of multiple antibodies had been used.
In the TRIGR cohort, children born to a mother with type 1
diabetes had a slightly lower but statistically significant risk of
developing beta cell autoimmunity than those born with a
father or a sibling with type 1 diabetes. However, difference
in risk of developing autoantibodies based on family history
type was not linked to differences in birthweight or growth
(height velocity or BMIwithin the first 2 years of life). Ongoing
efforts should likely focus on other genetic and epigenetic risks
factors, as well as immunological mechanisms, to further
advance our ability to identify those at risk of developing multi-
ple antibodies and progressing to type 1 diabetes.
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